论文部分内容阅读
目的:探讨加强临床免疫检验质量控制的方法及效果。方法:选取我院2011年1月至2012年1月检验的60份免疫检验血样为研究对象,对其进行质量控制,选择2009年1月至2010年1月没有进行质量控制的50份免疫检验血样为对照组,对两组检验结果及治疗效果进行比较。结果:质量控制组C-肽、Ca125、Ca199、INS、CEA及AFP各项平均变异指数明显低于对照组,差异有统计学意义。此外,质量控制组治疗总有效率高达96.67%,明显高于对照组的72%,差异有统计学意义,P<0.05。结论:加强临床免疫检验质量控制管理,能明显提高免疫检验结果的准确性,进而提高临床治疗效果。
Objective: To explore ways and effects of strengthening the quality control of clinical immunoassay. Methods: Sixty blood samples of immunoassay tested in our hospital from January 2011 to January 2012 were selected for quality control. Fifty immunoassays without quality control from January 2009 to January 2010 were selected Blood samples for the control group, the two test results and treatment effects were compared. Results: The average variation index of C-peptide, Ca125, Ca199, INS, CEA and AFP in quality control group was significantly lower than that in control group, the difference was statistically significant. In addition, the total effective rate of the quality control group was as high as 96.67%, which was significantly higher than that of the control group (72%), the difference was statistically significant (P <0.05). Conclusion: To strengthen the quality control management of clinical immunoassay can significantly improve the accuracy of the immunoassay results and improve the clinical therapeutic effect.